Claims for Patent: 8,778,340

Summary for Patent: 8,778,340

Title:	Anti-angiogenesis therapy for the treatment of ovarian cancer
Abstract:	This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
Inventor(s):	Dupont; Jakob (Hillsborough, CA), Irl; Cornelia (Basel, CH)
Assignee:	Genentech, Inc. (So. San Francisco, CA)
Application Number:	13/032,532
Patent Claims:	1. A method of treating a patient diagnosed with recurrent platinum-sensitive advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, comprising subjecting the patient to a treatment regimen combining carboplatin and gemcitabine with the concurrent administration of 15 mg/kg of an anti-VEGF antibody having a heavy chain variable region comprising the following amino acid sequence: TABLE-US-00017 (SEQ ID NO. 1) EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP HYYGSSHWYF DVWGQGTLVT VSS and a light chain variable region comprising the following amino acid sequence: TABLE-US-00018 (SEQ ID NO. 2) DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ GTKVEIKR followed by anti-VEGF antibody maintenance therapy, and wherein the treatment regimen effectively extends the progression free survival of the patient. 2. The method of claim 1, wherein said anti-VEGF antibody binds the same epitope as the monoclonal anti-VEGF antibody A4.6.1 produced by hybridoma ATCC HB 10709. 3. The method of claim 1, wherein the anti-VEGF antibody is a humanized antibody. 4. The method of claim 3, wherein the anti-VEGF antibody is a humanized A4.6.1 antibody or fragment thereof. 5. The method of claim 3, wherein the anti-VEGF antibody is bevacizumab. 6. The method of claim 1, wherein the carboplatin is administered at an area under the concentration-time curve (AUC) of 4. 7. The method of claim 1, wherein the gemcitabine is administered at 1000 mg/m.sup.2. 8. The method of claim 1, wherein the anti-VEGF antibody maintenance is administered at 15 mg/kg. 9. The method claim 1, wherein the progression free survival of the patient is extended by at least about 2.3 months or more compared to another patient not treated with anti-VEGF antibody. 10. The method of claim 1, wherein the patient is diagnosed with Stage III or Stage IV ovarian cancer.

Details for Patent 8,778,340

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2030-02-23